BIOMAT Database Logo BIOMAT Database Logo

siRNA targeting vaccinia virus double-stranded RNA binding protein [E3L] exerts potent antiviral effects. 2006

Rajnish S Dave, and James P McGettigan, and Tazeen Qureshi, and Matthias J Schnell, and Giuseppe Nunnari, and Roger J Pomerantz
The Dorrance H. Hamilton Laboratories, Division of Infectious Diseases, Center for Human Virology, Thomas Jefferson University, Philadelphia, PA 19107, USA. rajnish.dave@jefferson.edu

The Vaccinia virus gene, E3L, encodes a double-stranded RNA [dsRNA]-binding protein. We hypothesized that, owing to the critical nature of dsRNA in triggering host innate antiviral responses, E3L-specific small-interfering RNAs [siRNAs] should be effective antiviral agents against pox viruses, for which Vaccinia virus is an appropriate surrogate. In this study, we have utilized two human cell types, namely, HeLa and 293T, one which responds to interferon [IFN]-beta and the other produces and responds to IFN-beta, respectively. The antiviral effects were equally robust in HeLa and 293T cells. However, in the case of 293T cells, several distinct features were observed, when IFN-beta is activated in these cells. Vaccinia virus replication was inhibited by 97% and 98% as compared to control infection in HeLa and 293T cells transfected with E3L-specific siRNAs, respectively. These studies demonstrate the utility of E3L-specific siRNAs as potent antiviral agents for small pox and related pox viruses.

UI MeSH Term Description Entries
D007113 Immunity, Innate The capacity of a normal organism to remain unaffected by microorganisms and their toxins. It results from the presence of naturally occurring ANTI-INFECTIVE AGENTS, constitutional factors such as BODY TEMPERATURE and immediate acting immune cells such as NATURAL KILLER CELLS. Immunity, Native,Immunity, Natural,Immunity, Non-Specific,Resistance, Natural,Innate Immune Response,Innate Immunity,Immune Response, Innate,Immune Responses, Innate,Immunity, Non Specific,Innate Immune Responses,Native Immunity,Natural Immunity,Natural Resistance,Non-Specific Immunity
D007370 Interferon Type I Interferon secreted by leukocytes, fibroblasts, or lymphoblasts in response to viruses or interferon inducers other than mitogens, antigens, or allo-antigens. They include alpha- and beta-interferons (INTERFERON-ALPHA and INTERFERON-BETA). Interferons Type I,Type I Interferon,Type I Interferons,Interferon, Type I,Interferons, Type I
D008954 Models, Biological Theoretical representations that simulate the behavior or activity of biological processes or diseases. For disease models in living animals, DISEASE MODELS, ANIMAL is available. Biological models include the use of mathematical equations, computers, and other electronic equipment. Biological Model,Biological Models,Model, Biological,Models, Biologic,Biologic Model,Biologic Models,Model, Biologic
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D005814 Genes, Viral The functional hereditary units of VIRUSES. Viral Genes,Gene, Viral,Viral Gene
D006367 HeLa Cells The first continuously cultured human malignant CELL LINE, derived from the cervical carcinoma of Henrietta Lacks. These cells are used for, among other things, VIRUS CULTIVATION and PRECLINICAL DRUG EVALUATION assays. Cell, HeLa,Cells, HeLa,HeLa Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral
D001483 Base Sequence The sequence of PURINES and PYRIMIDINES in nucleic acids and polynucleotides. It is also called nucleotide sequence. DNA Sequence,Nucleotide Sequence,RNA Sequence,DNA Sequences,Base Sequences,Nucleotide Sequences,RNA Sequences,Sequence, Base,Sequence, DNA,Sequence, Nucleotide,Sequence, RNA,Sequences, Base,Sequences, DNA,Sequences, Nucleotide,Sequences, RNA

Related Publications

Rajnish S Dave, and James P McGettigan, and Tazeen Qureshi, and Matthias J Schnell, and Giuseppe Nunnari, and Roger J Pomerantz
Nuclear localization of a double-stranded RNA-binding protein encoded by the vaccinia virus E3L gene.
August 1993, Virology,
Rajnish S Dave, and James P McGettigan, and Tazeen Qureshi, and Matthias J Schnell, and Giuseppe Nunnari, and Roger J Pomerantz
Complementation of vaccinia virus lacking the double-stranded RNA-binding protein gene E3L by human cytomegalovirus.
May 2002, Journal of virology,
Rajnish S Dave, and James P McGettigan, and Tazeen Qureshi, and Matthias J Schnell, and Giuseppe Nunnari, and Roger J Pomerantz
Blockade of interferon induction and action by the E3L double-stranded RNA binding proteins of vaccinia virus.
May 2002, Journal of virology,
Rajnish S Dave, and James P McGettigan, and Tazeen Qureshi, and Matthias J Schnell, and Giuseppe Nunnari, and Roger J Pomerantz
The double-stranded RNA binding domain of the vaccinia virus E3L protein inhibits both RNA- and DNA-induced activation of interferon beta.
September 2009, The Journal of biological chemistry,
Rajnish S Dave, and James P McGettigan, and Tazeen Qureshi, and Matthias J Schnell, and Giuseppe Nunnari, and Roger J Pomerantz
The E3L gene of vaccinia virus encodes an inhibitor of the interferon-induced, double-stranded RNA-dependent protein kinase.
June 1992, Proceedings of the National Academy of Sciences of the United States of America,
Rajnish S Dave, and James P McGettigan, and Tazeen Qureshi, and Matthias J Schnell, and Giuseppe Nunnari, and Roger J Pomerantz
Vaccinia virus double-stranded RNA-binding protein E3 does not interfere with siRNA-mediated gene silencing in mammalian cells.
June 2007, Virus research,
Rajnish S Dave, and James P McGettigan, and Tazeen Qureshi, and Matthias J Schnell, and Giuseppe Nunnari, and Roger J Pomerantz
Identification of a conserved motif that is necessary for binding of the vaccinia virus E3L gene products to double-stranded RNA.
June 1993, Virology,
Rajnish S Dave, and James P McGettigan, and Tazeen Qureshi, and Matthias J Schnell, and Giuseppe Nunnari, and Roger J Pomerantz
Vaccinia virus subverts a mitochondrial antiviral signaling protein-dependent innate immune response in keratinocytes through its double-stranded RNA binding protein, E3.
November 2008, Journal of virology,
Rajnish S Dave, and James P McGettigan, and Tazeen Qureshi, and Matthias J Schnell, and Giuseppe Nunnari, and Roger J Pomerantz
Double-Stranded-RNA-Binding Protein 2 Participates in Antiviral Defense.
May 2020, Journal of virology,
Rajnish S Dave, and James P McGettigan, and Tazeen Qureshi, and Matthias J Schnell, and Giuseppe Nunnari, and Roger J Pomerantz
Double-stranded RNA in vaccinia virus infected cells.
June 1969, Nature,
Copied contents to your clipboard!